Active Ingredient(s):Siponimod FDA Approved: * March 26, 2019 Pharm Company: *NOVARTIS PHARMS CORP Category:Multiple Sclerosis
Siponimod, sold under the brand name Mayzent, is a selective sphingosine-1-phosphate receptor modulator for oral use that is used for multiple sclerosis (MS). It is intended for once-daily oral administration.
In March 2019, it was approved in the United States to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.&a...
* May have multiple approval dates, manufacturers, or labelers.